NJ A2240 | 2022-2023 | Regular Session

Note: Carry Foward to future A3621
Note: Carry Over of previous A2488
Note: Carry Over of previous S919

Status

Spectrum: Partisan Bill (Democrat 2-0)
Status: Introduced on February 7 2022 - 25% progression, died in committee
Action: 2022-02-07 - Introduced, Referred to Assembly Health Committee
Pending: Assembly Health Committee
Text: Latest bill text (Introduced) [HTML]

Summary

Prohibits excessive increases in prices charged for essential off-patent and generic prescription drugs and biological products.

Tracking Information

Register now for our free OneVote public service or GAITS Pro trial account and you can begin tracking this and other legislation, all driven by the real-time data of the LegiScan API. Providing tools allowing you to research pending legislation, stay informed with email alerts, content feeds, and share dynamic reports. Use our new PolitiCorps to join with friends and collegaues to monitor & discuss bills through the process.

Monitor Legislation or view this same bill number from multiple sessions or take advantage of our national legislative search.

Title

Prohibits excessive increases in prices charged for essential off-patent and generic prescription drugs and biological products.

Sponsors


History

DateChamberAction
2022-02-07AssemblyIntroduced, Referred to Assembly Health Committee

Same As/Similar To

A2240 (Carry Over) 2022-02-07 - Introduced, Referred to Assembly Health Committee
A2488 (Carry Over) 2020-02-03 - Introduced, Referred to Assembly Health Committee
S919 (Carry Over) 2020-01-27 - Introduced in the Senate, Referred to Senate Health, Human Services and Senior Citizens Committee
S1667 (Same As) 2022-02-14 - Introduced in the Senate, Referred to Senate Health, Human Services and Senior Citizens Committee

Subjects


New Jersey State Sources


Bill Comments

feedback